Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Holding EW?
Track your performance easily
EW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$58.93 - $96.12
Previous Close$70.2
Volume4.31M
Average Volume (3M)6.09M
Market Cap
$41.40B
Enterprise Value$37.73B
Total Cash (Recent Filing)$4.45B
Total Debt (Recent Filing)$706.70M
Price to Earnings (P/E)10.1
Beta1.38
Next Earnings
Jan 30, 2025EPS Estimate
$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.93
Shares Outstanding589,800,000
10 Day Avg. Volume5,006,177
30 Day Avg. Volume6,086,043
Standard Deviation0.10
R-Squared0.36
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)4.34
Price to Sales (P/S)6.81
Price to Cash Flow (P/CF)29.30
P/FCF Ratio32.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.42
Enterprise Value/Gross Profit8.16
Enterprise Value/Ebitda23.18
Forecast
1Y Price Target
$74.29Price Target Upside6.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe EARLY TAVR trial showed superiority of early TAVR intervention in patients who were asymptomatic, with significantly fewer experiencing death, stroke, or unplanned cardiovascular hospitalization compared to those under clinical surveillance.
Market PotentialThe market for TR could be larger than we think.
Regulatory ApprovalEvoque is the first and only approved transcatheter tricuspid valve replacement system, with an approval in Europe as well as the US.
Bears Say
Financial OutlookManagement's FY25 guidance suggests a further downside in estimates, with a lower adjusted EPS forecasted.
Market CompetitionThe biggest headwinds for Evoque adoption relate to the system's newness and high price, followed by the availability of a more familiar and less expensive repair option, ABT's TriClip.
Product PerformanceThe lack of a mortality benefit for TAVR over surveillance is the top criticism of the results and likely accounts for the 1% decline in EW's stock.
---
Ownership Overview
0.93% Insiders
21.89% Mutual Funds
18.24% Other Institutional Investors
35.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jan 30, 2025 which is in 70 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Oct 24, 2024. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.665 by $0.005.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is $0.56.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 589,800,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.665. Following the earnings report the stock price went down -1.379%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 546M.
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.29 (6.83% Upside)
$74.29 (6.83% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 60.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.93%
12-Months-Change
Fundamentals
Return on Equity
17.93%
Trailing 12-Months
Asset Growth
38.42%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q3 2024
0:00 / 0:00
---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$74.29
▲(6.83% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
21/34 ratings generated profit
1 Year Average Return
+10.56%
assigned a buy rating 22 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 61.76% of your transactions generating a profit, with an average return of +10.56% per trade.
---